AstraZeneca PLC (AZN) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - General Branche. Der Hauptsitz des Unternehmens ist in Cambridge, United Kingdom. Der aktuelle CEO ist Pascal Claude Roland Soriot.
AZN hat IPO-Datum 1993-05-12, 94,300 Vollzeitbeschäftigte, gelistet an der NYSE, eine Marktkapitalisierung von $316.85B.
AstraZeneca PLC is a global biopharmaceutical company engaged in the discovery, development, manufacturing, and commercialization of prescription medicines. The company maintains a diverse portfolio of marketed products across multiple therapeutic areas, including cardiovascular, renal, metabolic, and oncology treatments such as Tagrisso, Imfinzi, and Lynparza, alongside vaccines and rare disease medications including Vaxzevria and Soliris. AstraZeneca operates through a network of distributors and representative offices across the United Kingdom, Europe, the Americas, Asia, Africa, and Australasia, serving both primary and specialty care physicians. The company actively pursues innovation partnerships with organizations including Neurimmune AG, BenevolentAI, and Absci Corporation to advance drug discovery and development in areas such as neurodegenerative diseases, systemic lupus erythematosus, and oncology. Headquartered in Cambridge, United Kingdom, AstraZeneca was incorporated in 1992 and adopted its current name in 1999.